Idiopathic pulmonary fibrosis: Current concepts

被引:120
|
作者
Ryu, JH
Colby, TV
Hartman, TE
机构
[1] Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Internal Med, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Diagnost Radiol, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Pathol & Lab Med, Scottsdale, AZ USA
基金
美国国家卫生研究院;
关键词
D O I
10.4065/73.11.1085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic pulmonary fibrosis (LPF) is generally defined as a progressive, fibrosing inflammatory disease of the lung parenchyma of unknown cause. It is characterized by slowly increasing dyspnea, diffuse interstitial lung infiltrates, restrictive lung dysfunction, and impaired gas exchange. Ultimately, it is fatal in most patients, and treatment options remain unsatisfactory. The advent of high-resolution computed tomography of the chest and modifications in the histopathologic classification of interstitial pneumonias have reshaped the concept of IPF, Although initially thought to be a relatively specific clinicopathologic entity, it seems likely that IPF as previously defined is a heterogeneous disorder consisting of several clinicopathologic entities with differing histopathologic patterns, clinical course, response to therapy, and prognosis. The most common histologic pattern in cases previously defined as IPF is usual interstitial pneumonia, which is associated with a median survival of less than 3 years. For accurate prognosis and optimal management of patients, the clinician should attempt to be as precise as possible in distinguishing various clinico-pathologic entities that have been included under the clinical heading of IPF, In the future, we recommend that the use of the term "idiopathic pulmonary fibrosis" be restricted to patients with usual interstitial pneumonia and that clinicians recognize the fact that other idiopathic interstitial pneumonias do not have the same prognostic effect traditionally ascribed to IPF.
引用
收藏
页码:1085 / 1101
页数:17
相关论文
共 50 条
  • [21] Diagnosis of idiopathic pulmonary fibrosis: Current issues
    Prasad, Rajendra
    Gupta, Nikhil
    Singh, Abhijeet
    Gupta, Pawan
    INTRACTABLE & RARE DISEASES RESEARCH, 2015, 4 (02) : 65 - 69
  • [22] Idiopathic pulmonary fibrosis: current trends in management
    Raghu, G
    Chang, J
    CLINICS IN CHEST MEDICINE, 2004, 25 (04) : 621 - +
  • [23] Current and future treatment for idiopathic pulmonary fibrosis
    Choi, Won-Il
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (04): : 256 - 263
  • [24] Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis
    du Bois, RM
    CLINICS IN CHEST MEDICINE, 2006, 27 (01) : S17 - +
  • [25] Current criteria for lung transplantation in idiopathic pulmonary fibrosis
    Navarro, JG
    Galván, AP
    Carro, LM
    ARCHIVOS DE BRONCONEUMOLOGIA, 2002, 38 (05): : 251 - 252
  • [26] The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
    Martinez, Fernando J.
    Chisholm, Alison
    Collard, Harold R.
    Flaherty, Kevin R.
    Myers, Jeffrey
    Raghu, Ganesh
    Walsh, Simon L. F.
    White, Eric S.
    Richeldi, Luca
    LANCET RESPIRATORY MEDICINE, 2017, 5 (01): : 61 - 71
  • [27] Current and novel drug therapies for idiopathic pulmonary fibrosis
    Adamali, Huzaifa I.
    Maher, Toby M.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 : 261 - 271
  • [28] A review of current and novel therapies for idiopathic pulmonary fibrosis
    Rafii, Rokhsara
    Juarez, Maya M.
    Albertson, Timothy E.
    Chan, Andrew L.
    JOURNAL OF THORACIC DISEASE, 2013, 5 (01) : 48 - 73
  • [29] Current and Novel Treatment Modalities of Idiopathic Pulmonary Fibrosis
    Arshad, Mahnoor
    Athar, Zoraize Moeez
    Hiba, Tasneem
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [30] Current and future therapeutic approaches in idiopathic pulmonary fibrosis
    Bouros, D
    Antoniou, KM
    EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (04) : 693 - 702